Radnor’s L.E.A.F. Pharmaceuticals – a global pharmaceutical company with a mission to discover, develop, and commercialize innovative and safe therapies for cancer – has announced the establishment of L.E.A.F. Rwanda Ltd., a biotechnology company headquartered in Kigali, Rwanda.
L.E.A.F. Rwanda, a fully owned subsidiary of L.E.A.F. Pharmaceuticals, will focus on establishing Rwanda as a hub for biotechnology Research and Development, as well as pharmaceutical manufacturing in Africa. This Kigali-headquartered company will work to attract and retain highly skilled biotechnology scientists and clinical researchers from Africa and beyond, in a quest to discover and develop innovative medicines against diseases that predominantly afflict the health of the African population.
L.E.A.F. Rwanda will partner with L.E.A.F. Pharmaceuticals to facilitate advanced skills transfer to the continent, for long-term sustainability of a robust biotechnology industry in Africa.
“Historically, innovative lifesaving medicines have taken too long to reach the African population, if at all,” said Dr. Clet Niyikiza, the Founder, President, and CEO of L.E.A.F. Pharmaceuticals. “A key component of L.E.A.F. Rwanda’s mission is to focus on expeditiously making available such medicines to the African population.”
Since L.E.A.F. Pharmaceuticals began operations in August 2014, the company has filed nearly a dozen patent applications to protect its intellectual property. L.E.A.F. Rwanda, in partnership with L.E.A.F. Pharmaceuticals, anticipates making available its first anti-cancer medicine in Africa starting in 2019.